Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life. Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consu...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Guilan University of Medical Sciences
2019-11-01
|
Series: | Caspian Journal of Neurological Sciences |
Subjects: | |
Online Access: | http://cjns.gums.ac.ir/article-1-291-en.html |
id |
doaj-33adc53f06964337ae5ca03018212067 |
---|---|
record_format |
Article |
spelling |
doaj-33adc53f06964337ae5ca030182120672020-11-24T22:00:00ZengGuilan University of Medical SciencesCaspian Journal of Neurological Sciences2423-48182423-48182019-11-0154151160Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and CinnovexAlia Saberi0Hamidreza Hatamian1Amirreza Ghayeghran2Fatemeh Mola Hosseini3Sama Noroozi Guilandehi4Sajjad Rezaei5Fatemeh Shafaei6 Neuroscience Research Center, Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran School of Medicine, Guilan University of Medical Sciences, Rasht, Iran Department of Psychology, University of Guilan, Rasht, Iran Neuroscience Research Center, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life. Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consuming Fingolimod and Cinnovex. Materials & Methods: In an analytical cross-sectional study, 106 patients with Relapsing-Remitting MS (RRMS) referred to specialized neurology clinics of Guilan University of Medical Sciences were selected for the study using a convenience sampling method (52 patients consuming Fingolimod and 54 patients consuming Cinnovex). Then, we collected their demographic information and medical profile. The patients were assessed by the Hamburg quality of life questionnaire in MS. The obtained data were analyzed in SPSS V. 22 using the Chi-square test, independent t-test, Mann-Whitney U, one-way and multivariate analysis of covariance. Results: There was a significant difference between the two groups in terms of age, number of attacks in the last 6 months, and educational level (P<0.05). After controlling confounding variables, it was found that consumers of Fingolimod had a better quality of life. At the subscales level, this difference was significant only in the mood dimension (F=6.931, P=0.011, η=0.12). Conclusion: Patients consuming Fingolimod reported a better quality of life compared to consumers of Cinnovex. This improvement was mainly found in mood scores.http://cjns.gums.ac.ir/article-1-291-en.htmlmultiple sclerosis (ms)quality of life (qol)fingolimod hydrochloride |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alia Saberi Hamidreza Hatamian Amirreza Ghayeghran Fatemeh Mola Hosseini Sama Noroozi Guilandehi Sajjad Rezaei Fatemeh Shafaei |
spellingShingle |
Alia Saberi Hamidreza Hatamian Amirreza Ghayeghran Fatemeh Mola Hosseini Sama Noroozi Guilandehi Sajjad Rezaei Fatemeh Shafaei Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex Caspian Journal of Neurological Sciences multiple sclerosis (ms) quality of life (qol) fingolimod hydrochloride |
author_facet |
Alia Saberi Hamidreza Hatamian Amirreza Ghayeghran Fatemeh Mola Hosseini Sama Noroozi Guilandehi Sajjad Rezaei Fatemeh Shafaei |
author_sort |
Alia Saberi |
title |
Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex |
title_short |
Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex |
title_full |
Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex |
title_fullStr |
Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex |
title_full_unstemmed |
Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex |
title_sort |
comparing the quality of life in patients with multiple sclerosis consuming fingolimod and cinnovex |
publisher |
Guilan University of Medical Sciences |
series |
Caspian Journal of Neurological Sciences |
issn |
2423-4818 2423-4818 |
publishDate |
2019-11-01 |
description |
Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life.
Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consuming Fingolimod and Cinnovex.
Materials & Methods: In an analytical cross-sectional study, 106 patients with Relapsing-Remitting MS (RRMS) referred to specialized neurology clinics of Guilan University of Medical Sciences were selected for the study using a convenience sampling method (52 patients consuming Fingolimod and 54 patients consuming Cinnovex). Then, we collected their demographic information and medical profile. The patients were assessed by the Hamburg quality of life questionnaire in MS. The obtained data were analyzed in SPSS V. 22 using the Chi-square test, independent t-test, Mann-Whitney U, one-way and multivariate analysis of covariance.
Results: There was a significant difference between the two groups in terms of age, number of attacks in the last 6 months, and educational level (P<0.05). After controlling confounding variables, it was found that consumers of Fingolimod had a better quality of life. At the subscales level, this difference was significant only in the mood dimension (F=6.931, P=0.011, η=0.12).
Conclusion: Patients consuming Fingolimod reported a better quality of life compared to consumers of Cinnovex. This improvement was mainly found in mood scores. |
topic |
multiple sclerosis (ms) quality of life (qol) fingolimod hydrochloride |
url |
http://cjns.gums.ac.ir/article-1-291-en.html |
work_keys_str_mv |
AT aliasaberi comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex AT hamidrezahatamian comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex AT amirrezaghayeghran comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex AT fatemehmolahosseini comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex AT samanorooziguilandehi comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex AT sajjadrezaei comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex AT fatemehshafaei comparingthequalityoflifeinpatientswithmultiplesclerosisconsumingfingolimodandcinnovex |
_version_ |
1725845990036996096 |